Literature DB >> 23097577

A cough conundrum in a patient with a previous history of BCG immunotherapy for bladder cancer.

Arpan R Mehta1, Puja R Mehta, Rajesh L Mehta.   

Abstract

We describe a non-smoker who presented with a persistent cough, weight loss and general malaise, and had a medical history of bladder carcinoma that had been successfully treated with intravesical BCG immunotherapy. Radiology revealed hilar lymphadenopathy, a predominantly mid-zone and lower-zone lung parenchymal nodular pattern with a perilymphatic distribution, a few thickened interlobular septae, and small pleural effusions bilaterally. The T-SPOT.TB blood test was negative. Video-assisted thoracoscopic surgery showed multiple pleural nodules, the histopathology of which showed multiple well-defined non-caseating granulomata. The patient was started on antituberculosis medication for presumed BCGosis--a systemic complication of previous BCG immunotherapy--and the patient showed an excellent clinical and radiological response. This case further adds to previous reports and reinforces the recommendation that all patients should be made fully aware of the potential systemic and delayed complications of BCG immunotherapy when they are consented for treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23097577      PMCID: PMC4544233          DOI: 10.1136/bcr-2012-007327

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Discordance among commercially available diagnostics for latent tuberculosis infection.

Authors:  James D Mancuso; Gerald H Mazurek; David Tribble; Cara Olsen; Naomi E Aronson; Lawrence Geiter; Donald Goodwin; Lisa W Keep
Journal:  Am J Respir Crit Care Med       Date:  2011-12-08       Impact factor: 21.405

Review 2.  Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis.

Authors:  M Sester; G Sotgiu; C Lange; C Giehl; E Girardi; G B Migliori; A Bossink; K Dheda; R Diel; J Dominguez; M Lipman; J Nemeth; P Ravn; S Winkler; E Huitric; A Sandgren; D Manissero
Journal:  Eur Respir J       Date:  2010-09-16       Impact factor: 16.671

3.  Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma.

Authors:  A Böhle; C Nowc; A J Ulmer; J Musehold; J Gerdes; A G Hofstetter; H D Flad
Journal:  Cytokine       Date:  1990-05       Impact factor: 3.861

4.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-1998. A 57-year-old man with fever and jaundice after intravesical instillation of bacille Calmette-Guérin for bladder cancer.

Authors: 
Journal:  N Engl J Med       Date:  1998-09-17       Impact factor: 91.245

5.  Sensitivity of BCG to modern antibiotics.

Authors:  C Durek; S Rüsch-Gerdes; D Jocham; A Böhle
Journal:  Eur Urol       Date:  2000       Impact factor: 20.096

Review 6.  Bacille Calmette-Guérin in superficial transitional cell carcinoma.

Authors:  N A Mungan; J A Witjes
Journal:  Br J Urol       Date:  1998-08

Review 7.  Practical approaches to the prevention and treatment of adverse reactions to BCG.

Authors:  A P van der Meijden
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

8.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

9.  Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.

Authors:  C Durek; A Jurczok; H Werner; D Jocham; A Bohle
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

Review 10.  Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin.

Authors:  J K Izes; W Bihrle; C B Thomas
Journal:  J Urol       Date:  1993-11       Impact factor: 7.450

View more
  5 in total

1.  Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy.

Authors:  Vasiliki Delimpoura; Konstantinos Samitas; Ioannis Vamvakaris; Eleftherios Zervas; Mina Gaga
Journal:  BMJ Case Rep       Date:  2013-10-10

2.  BCG-osis following intravesical BCG treatment leading to miliary pulmonary nodules, penile granulomas and a mycotic aortic aneurysm.

Authors:  David Mark Smith
Journal:  BMJ Case Rep       Date:  2016-07-14

3.  Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.

Authors:  Patrick Gellings; Michelle Galeas-Pena; Lisa A Morici
Journal:  Clin Exp Med       Date:  2022-01-25       Impact factor: 3.984

4.  Fever of unknown origin and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette-Guerin (BCG) infection after intravesical instillation.

Authors:  Pedro Dammert; Ziad Boujaoude; William Rafferty; Jonathan Kass
Journal:  BMJ Case Rep       Date:  2013-04-09

5.  Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder.

Authors:  Fatehi Elzein; Nada Albogami; Mustafa Saad; Nazik El Tayeb; Abdullah Alghamdi; Ghaleb Elyamany
Journal:  Clin Med Insights Case Rep       Date:  2016-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.